Literature DB >> 5472041

[Two years experience with L-DOPA in association with a decarboxylase inhibitor].

J Siegfried.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5472041

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN： 0035-3787            Impact factor:   2.607


× No keyword cloud information.
  7 in total

1.  Brocresine in Parkinson's disease. Action of a peripheral and central decarboxylase inhibitor in potentiating levodopa.

Authors:  P M Howse; W B Matthews
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

2.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

3.  Changes in taste under L-DOPA therapy.

Authors:  J Siegfried; H Zumstein
Journal:  Z Neurol       Date:  1971

4.  Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.

Authors:  J Constantinidis; J Siegfried; T L Frigyesi; R Tissot
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

5.  [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].

Authors:  E Schneider; P A Fischer; P Jacobi; H Maxion
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1973-03-19

6.  Decrease of the 3,4-dihydroxyphenylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA.

Authors:  S S Tate; R Sweet; F H McDowell; A Meister
Journal:  Proc Natl Acad Sci U S A       Date:  1971-09       Impact factor: 11.205

7.  Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1972-06-10       Impact factor: 8.262
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.